Therapy News and Research

RSS

Researchers identify cellular channels critical for hearing

Ending a 30-year search by scientists, researchers at Boston Children's Hospital have identified two proteins in the inner ear that are critical for hearing, which, when damaged by genetic mutations, cause a form of delayed, progressive hearing loss. Findings were published online July 18 by the journal Neuron.

19 Jul 2013

C. difficile bacteriophage provides new weapon to battle against superbugs

IFR microbiologists are reinvigorating a way of battling C. difficile infections that they hope will help overcome the growing problem of antibiotic resistant superbugs in hospitals.

19 Jul 2013

Early diagnosis of AD may prevent psychological and behavioral symptoms

Persons with Alzheimer's disease are able to manage their everyday activities longer and they suffer from less psychological and behavioural symptoms if the diagnosis is made and treatment begun at a very early phase of the disease, indicates a recent study conducted at the University of Eastern Finland.

19 Jul 2013

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

19 Jul 2013

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Cubist Pharmaceuticals, Inc. today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation.

19 Jul 2013

Three key technologies receive £85 million investment for capital equipment from EPSRC

Three key technologies, identified in the pre-budget statement by The Chancellor of the Exchequer as part of the government's 'eight great technologies' to drive UK growth, are to receive an -85 million investment for capital equipment.

19 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

Audentes Therapeutics closes $30 million Series A financing

Audentes Therapeutics, Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing.

18 Jul 2013

Study brings new hope for patients with metastatic prostate cancer

A study of a new radiotherapeutic drug published this week in the New England Journal of Medicine brings fresh hope for a particular group of cancer patients that otherwise suffer and ultimately die from the disease -- those with prostate cancer that has spread to their bones and has failed to be controlled by hormone deprivation drugs.

18 Jul 2013

Quest Diagnostics completes sale of ibrutinib commercialization rights to Royalty Pharma

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today that it has completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, for $485 million in cash.

From Quest Diagnostics 18 Jul 2013

Inovio's electroporation technology enhances ability of DNA therapy to stimulate blood vessel growth

Inovio Pharmaceuticals, Inc. announced today that the use of its proprietary electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth, which may be beneficial for the treatment of critical limb ischemia and other forms of peripheral arterial disease.

18 Jul 2013

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Filariasis refers to a group of diseases caused by parasitic worms, which are transmitted by blood feeding insects. Two species infect the lymphatic and blood systems causing lymphatic filariasis, which in some people can lead to gross swelling of the limbs and 'elephantiasis'.

18 Jul 2013

CHOP-led research increases numbers of patients who could be treated with gene therapy

Gene therapy researchers have produced a bioengineered decoy that fools the immune system and prevents it from mistakenly defeating the benefits delivered by a corrective gene.

18 Jul 2013

Discovery provides evidence that genetic defect responsible for Down syndrome can be suppressed

Scientists at the University of Massachusetts Medical School are the first to establish that a naturally occurring X chromosome "off switch" can be rerouted to neutralize the extra chromosome responsible for trisomy 21, also known as Down syndrome, a genetic disorder characterized by cognitive impairment.

18 Jul 2013

Breast cancer pilot study: Patients benefit from treatments guided by molecular profiling

The Side-Out Foundation's breast cancer pilot study, led by the Translational Genomics Research Institute, Translational Drug Development and Scottsdale Healthcare, has shown that cancer patients do better when their treatment is guided by molecular profiling.

18 Jul 2013

Researchers discover new protein that encourages ‘bad’ blood vessel growth

The discovery of a protein that encourages blood vessel growth, and especially 'bad' blood vessels - the kind that characterise diseases as diverse as cancer, age-related macular degeneration and rheumatoid arthritis - has been reported in the journal Nature.

18 Jul 2013

Single dose of methylphenidate can reduce risk of falls among elderly adults

Ben-Gurion University of the Negev researchers have discovered that a single dose of methylphenidate, used to treat Attention Deficit Hyperactivity Disorder and narcolepsy, helps to improve balance control during walking, hence reducing the risk of falls among elderly adults.

18 Jul 2013

Novel way to fine-tune activity of cells' protein-disposing machinery with cancer-fighting effects

Molecular biologists in the School of Medicine at The University of Texas Health Science Center San Antonio have found a novel way to fine-tune the activity of cells' protein-disposing machinery, with potentially cancer-fighting effects.

18 Jul 2013

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.

18 Jul 2013

Therapy News and Research

Researchers identify cellular channels critical for hearing

C. difficile bacteriophage provides new weapon to battle against superbugs

Early diagnosis of AD may prevent psychological and behavioral symptoms

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Three key technologies receive £85 million investment for capital equipment from EPSRC

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Audentes Therapeutics closes $30 million Series A financing

Study brings new hope for patients with metastatic prostate cancer

Quest Diagnostics completes sale of ibrutinib commercialization rights to Royalty Pharma

Inovio's electroporation technology enhances ability of DNA therapy to stimulate blood vessel growth

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

CHOP-led research increases numbers of patients who could be treated with gene therapy

Discovery provides evidence that genetic defect responsible for Down syndrome can be suppressed

Breast cancer pilot study: Patients benefit from treatments guided by molecular profiling

Researchers discover new protein that encourages ‘bad’ blood vessel growth

Single dose of methylphenidate can reduce risk of falls among elderly adults

Novel way to fine-tune activity of cells' protein-disposing machinery with cancer-fighting effects

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News